Novartis raises 2019 guidance, helped by Sandoz generics unit

Credit: REUTERS/ARND WIEGMANN

Novartis lifted full-year sales and profit targets on Thursday, helped by innovative medicine sales and as the Swiss drugmaker's slimmed-down Sandoz generics unit saw accelerating revenue in markets outside the United States.

ZURICH, July 18 (Reuters) - Novartis NOVN.S lifted full-year sales and profit targets on Thursday, helped by innovative medicine sales and as the Swiss drugmaker's slimmed-down Sandoz generics unit saw accelerating revenue in markets outside the United States.

Core operating income rose 20% in constant currencies to $3.6 billion, while sales were up 8% to $11.8 billion, compared to the $11.54 billion forecast by 10 analysts in a Refinitiv poll.

The Basel-based company now expects 2019 core operating income to grow at low-double-digit to mid-teens percentages, faster than the previous high-single-digit percentage rate target. Sales expectations were also raised, with growth now seen in the mid to high-single digit range.

(Reporting by John Miller Editing by Thomas Seythal)

((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More